This funding opportunity supports investigator-initiated research to analytically and clinically validate molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response or resistance. Projects may include assay harmonization across labs and require multidisciplinary teams. The UH2 phase supports analytical validation within 2 years, and the UH3 phase supports clinical validation within 3 years using well-annotated biospecimens from clinical trials or studies.
Eligible applicants include U.S. institutions such as tribal governments, public and private higher education institutions, nonprofits, small businesses, government entities, and others. Foreign organizations are not eligible to apply, but foreign components of U.S. organizations are allowed.
